Sight Sciences, Inc.
$8.28+6.8%1Y+94.8%
Mentions · last 7 days
25+11%
Price updated 10h ago·X counts updated 8h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $SGHT, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Devices sits in its cycle right now — and what that implies for $SGHT.
Medical - Devices
No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.
Industry benchmark
26-name peer basket
+7.5%YTD
+29.0%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-12.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-29.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-33.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-7.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
4.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-50.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
88.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.08$-0.18+56.4%
Q1 2026May 6, 2026$-0.24$-0.19-26.3%
Q4 2025Mar 4, 2026$-0.08$-0.15+46.7%
Q3 2025Nov 6, 2025$-0.16$-0.26+38.5%
Next earningsThu, Nov 5·consensus EPS $-0.13
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$23.4M+19.5%91.4%-16.6%$-0.08$-12.8M
Q1 FY26$19.7M+12.5%86.2%-63.0%$-0.24$-7.1M
Q4 FY25$20.4M+6.9%87.3%-18.0%$-0.08$-1.7M
Q3 FY25$19.9M-1.2%86.4%-39.7%$-0.16$-8.9M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$86.1M$85.5M – $86.8M-$0.78-$0.99 – -$0.605
FY27$95.8M$94.3M – $97.9M-$0.67-$0.93 – -$0.385
FY28$104.7M$99.5M – $109.1M-$0.56-$0.94 – -$0.014
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.84%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+53.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+46.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 35.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.385-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeAug 108-K — Item 5.02: Officer or director change
AI summary
8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary
8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
8-KPress release / Reg FDMay 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDApr 238-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 308-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 48-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 7 other (2 10-Qs · 2 proxys · 1 SD · 1 13G) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
More in Medical - Devices
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $SGHT on X in the last 7 days.